Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP160723.RAccE9_fTfzRMa6XTwU70WCB6evM9FKg7WCSExgKH0CF8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP160723.RAccE9_fTfzRMa6XTwU70WCB6evM9FKg7WCSExgKH0CF8130_assertion type Assertion NP160723.RAccE9_fTfzRMa6XTwU70WCB6evM9FKg7WCSExgKH0CF8130_head.
- NP160723.RAccE9_fTfzRMa6XTwU70WCB6evM9FKg7WCSExgKH0CF8130_assertion description "[The positive expression rates of COX-2 were 10.0%, 35.7%, 37.8%, 41.7% and 69.5% in CSG, GA, IM, dysplasia and gastric cancer, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP160723.RAccE9_fTfzRMa6XTwU70WCB6evM9FKg7WCSExgKH0CF8130_provenance.
- NP160723.RAccE9_fTfzRMa6XTwU70WCB6evM9FKg7WCSExgKH0CF8130_assertion evidence source_evidence_literature NP160723.RAccE9_fTfzRMa6XTwU70WCB6evM9FKg7WCSExgKH0CF8130_provenance.
- NP160723.RAccE9_fTfzRMa6XTwU70WCB6evM9FKg7WCSExgKH0CF8130_assertion SIO_000772 15334675 NP160723.RAccE9_fTfzRMa6XTwU70WCB6evM9FKg7WCSExgKH0CF8130_provenance.
- NP160723.RAccE9_fTfzRMa6XTwU70WCB6evM9FKg7WCSExgKH0CF8130_assertion wasDerivedFrom befree-20140225 NP160723.RAccE9_fTfzRMa6XTwU70WCB6evM9FKg7WCSExgKH0CF8130_provenance.
- NP160723.RAccE9_fTfzRMa6XTwU70WCB6evM9FKg7WCSExgKH0CF8130_assertion wasGeneratedBy ECO_0000203 NP160723.RAccE9_fTfzRMa6XTwU70WCB6evM9FKg7WCSExgKH0CF8130_provenance.